BPC-157 for Gut Healing: Mechanisms, Animal Evidence, and What We Still Do Not Know
Explore the clinic directoryIn this article
Oral BPC-157 for gut health is supported by rodent studies, not human trials: in rats, BPC-157 given by mouth or in drinking water healed stomach ulcers, colitis and intestinal fistulas, helped by the fact that the peptide stays stable in gastric juice. No randomized controlled trial has tested oral BPC-157 for any human gut condition, it is not FDA approved for any use, and the 250 to 500 mcg daily doses integrative practitioners use are extrapolated from animal work.
At a Glance
- BPC-157 (Body Protection Compound-157, also coded PL 14736 and called bepecin) is a synthetic 15-amino-acid peptide derived from a protein in human gastric juice, studied mainly by Dr. Predrag Sikiric’s group at the University of Zagreb.
- Oral BPC-157 healed gastric ulcers, colitis and intestinal fistulas in rats when given by stomach tube or in drinking water, according to studies including Xue et al. (2004) and Klicek et al. (2008).
- The proposed mechanism combines new blood vessel growth (angiogenesis), growth factor signaling and modulation of the nitric oxide system, based on cell and animal studies.
- Human randomized controlled trial data does not yet exist. A phase II ulcerative colitis program under the code PL 14736 never produced a full peer-reviewed report, according to Sikiric et al. (2012).
- Available as oral capsules and injectable forms. BPC-157 is not FDA-approved for any indication, and FDA flagged it in 2023 for possible immune reactions and impurity risks in compounded products.
BPC-157 has developed a significant following in the biohacking and integrative medicine communities, often described as a “healing peptide” for its effects on gut tissue, tendons, and wound repair. The enthusiasm is not entirely unfounded. The animal data is genuinely impressive, spanning decades of research from the laboratory of Dr. Predrag Sikiric at the University of Zagreb. But there is a critical gap between animal study results and human clinical evidence, and understanding that gap is essential before making any decisions about use.
This is a case where the science is real, the human evidence is thin, and the practical decisions involve more uncertainty than most practitioners will admit.
What BPC-157 Is
BPC stands for Body Protection Compound. BPC-157 is a 15-amino acid sequence (hence “pentadecapeptide”) that was isolated from human gastric juice and found to have remarkable tissue-protective properties in animal models. It is not a naturally occurring peptide in the classical sense but rather a research compound derived from a larger gastric protein. In the research literature it also appears as BPC 157, PL 14736, PL-10 and bepecin.
The full amino acid sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is highly stable in gastric acid, which is why oral administration retains activity, unlike most peptides that are broken down during digestion. This oral bioavailability is one of the features that distinguishes BPC-157 from most therapeutic peptides, which require injection to avoid GI degradation. The BPC-157 treatment guide covers its uses beyond the gut, including tendon and soft tissue repair.
Does Oral BPC-157 Work for Gut Health?
Oral BPC-157 has healed gut injuries in rats and mice, and it has not been tested for any gut condition in a published human trial. The animal results are consistent across ulcer, colitis and fistula models, and most of them come from one research group in Zagreb.
Oral dosing is plausible for the gut because BPC-157 stays intact in human gastric juice for more than 24 hours, according to a 2024 review by Sikiric and colleagues in Inflammopharmacology. In rat studies, BPC-157 given in drinking water at 10 mcg/kg helped close persistent colocutaneous fistulas (Klicek et al., 2008), and BPC-157 given by stomach tube reduced ulcer area in acute and chronic gastric ulcer models (Xue et al., 2004).
Route still matters. Xue et al. (2004) found that intramuscular BPC-157 worked better than intragastric dosing in rat ulcer models, so oral use is not automatically the stronger choice for the gut. Human absorption, the right dose and the right duration remain unknown.
Which gut conditions do practitioners use BPC-157 for?
Practitioners use BPC-157 off label for inflammatory bowel disease, meaning Crohn’s disease and ulcerative colitis, for irritable bowel syndrome (IBS), for suspected leaky gut or increased intestinal permeability, and for stomach irritation linked to NSAID pain relievers. Some patients also ask about it alongside SIBO treatment. Every one of these uses rests on animal data rather than human trials.
Mechanisms for GI Repair
The mechanistic research on BPC-157 is the strongest part of its evidence base. Multiple pathways have been identified in cell and animal studies.
Angiogenesis
BPC-157 strongly stimulates angiogenesis, the formation of new blood vessels, in GI tissue. It upregulates vascular endothelial growth factor (VEGF) receptor expression and activates the VEGFR2-Akt-eNOS signaling pathway. In models of colitis and gastric ulcers, this translates to faster vascular bed restoration in damaged tissue. Blood vessel formation is rate-limiting for mucosal healing; without adequate blood supply, tissue regeneration stalls regardless of other repair signals.
Growth Factor Upregulation
BPC-157 is reported to work alongside the growth factors that drive mucosal cell proliferation and migration during ulcer healing: epidermal growth factor (EGF), fibroblast growth factor (FGF), vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF). According to a 2012 review by Sikiric et al. in Current Medicinal Chemistry, BPC-157 stimulates expression of the early growth response 1 (egr-1) gene, which drives cytokine and growth factor production and early collagen formation. A 2018 review by Seiwerth and colleagues reported that BPC-157 was consistently effective across esophagus, stomach, duodenum and lower GI injury models when given orally, by injection or locally.
Nitric Oxide System
Nitric oxide (NO) plays a dual role in GI health: baseline NO production by constitutive NOS enzymes maintains mucosal blood flow and integrity, while excessive inducible NOS (iNOS) activation in inflammation drives tissue damage. BPC-157 modulates this balance, increasing constitutive NO production while dampening pathological iNOS activity. This explains in part its anti-inflammatory effects in colitis models without causing the immune suppression associated with steroids.
Gut-Brain Axis Effects
BPC-157 also acts on the gut-brain axis through interactions with dopaminergic and serotonergic systems. In animal models, it reduces stress-induced gastric ulcers and modulates the hypothalamic-pituitary-adrenal (HPA) axis response to stress. This suggests potential utility for stress-related GI conditions like functional dyspepsia and irritable bowel syndrome, though no human trials exist for these applications.
Animal Evidence: What the Studies Show
Gastric Ulcers
The gastric ulcer data is the most extensive. Across more than 30 published studies from Sikiric’s group and independent researchers, BPC-157 consistently accelerates ulcer healing in rat models of NSAID-induced ulcers, ethanol-induced ulcers, and acetic acid ulcers. An independent study by Xue et al. in the World Journal of Gastroenterology (2004) found that BPC-157 at the higher doses tested inhibited ulcer formation by 45.7% to 65.6% across most rat models, given either by stomach tube or by intramuscular injection. Comparable human data does not exist.
Inflammatory Bowel Disease
In rat colitis models, BPC-157 reduces visible lesions, restores blood supply to the injured colon and normalizes markers of oxidative stress, according to a 2017 study from the Zagreb group in the World Journal of Gastroenterology that combined colitis with ischemia and reperfusion. The same group reports that BPC-157 outperformed standard agents in several GI injury models, including ranitidine and omeprazole in persistent gastrocutaneous fistulas (Skorjanec et al., Digestive Diseases and Sciences, 2009). These comparisons come largely from the developers’ own laboratory and have not been tested against standard IBD drugs such as mesalamine or sulfasalazine in people.
Intestinal Fistulas
One of the most striking demonstrations of BPC-157’s healing effect is in intestinal fistula models. Intestinal fistulas are notoriously difficult to treat even with modern medicine. Klicek et al. (Journal of Pharmacological Sciences, 2008) showed that BPC-157 given in drinking water or by injection healed persistent colocutaneous fistulas in rats, which showed very poor spontaneous healing over 28 days in untreated animals. The same group later reported similar results for gastrocutaneous, esophagocutaneous, colovesical and rectovaginal fistulas in rats.
Leaky Gut and Intestinal Permeability
Several animal studies show BPC-157 reduces intestinal permeability in NSAIDs-induced and stress-induced models. It upregulates tight junction proteins (occludin, claudin, ZO-1) that maintain epithelial barrier integrity. This is the basis for its use in integrative medicine for “leaky gut syndrome,” though that diagnosis itself remains contested in mainstream gastroenterology.
| Condition | Evidence Type | Evidence Grade | Key Finding |
|---|---|---|---|
| Gastric ulcers | Animal models (rodent) | Strong (animal), Absent (human) | Accelerates healing vs. controls |
| Colitis / IBD | Animal models | Strong (animal), Absent (human) | Reduces colitis lesions in rodent models, mostly in studies from one laboratory |
| Intestinal fistulas | Animal models | Preliminary | Closed persistent colocutaneous fistulas in rats (Klicek et al., 2008) |
| Leaky gut | Animal models | Preliminary | Tight junction upregulation |
| Human GI conditions | Case reports only | Insufficient | No RCTs published as of 2025 |
Oral vs. Injectable BPC-157
This is a practical question for anyone considering BPC-157. The compound has been tested in both oral and systemic (subcutaneous or intramuscular) forms in animal studies, with activity documented by both routes.
For GI applications specifically, the oral route makes logical sense. BPC-157 is stable in gastric acid, meaning it survives the stomach environment and can act locally on the GI mucosa before any systemic absorption occurs. This local GI contact likely accounts for a significant portion of its benefit in ulcer and colitis models. For systemic effects (tendon healing, systemic anti-inflammatory effects), injection produces more reliable systemic concentrations.
Most research protocols have used 10 mcg/kg in animal models, which translates to approximately 700 mcg (0.7 mg) for a 70 kg human. Practitioners in the integrative space typically recommend oral doses of 250-500 mcg daily for gut applications. There is no pharmacokinetic data establishing optimal human dosing.
The table below sets the two routes side by side using only what the animal studies and this page already state.
| Attribute | Oral BPC-157 | Injectable BPC-157 |
|---|---|---|
| Stability | Stays intact in human gastric juice for more than 24 hours, per Sikiric et al. (2024). | Bypasses the stomach entirely. |
| Gut evidence in animals | Healed ulcers, colitis and fistulas in rats given BPC-157 in drinking water or by stomach tube. | Healed the same lesions given intraperitoneally or intramuscularly, and outperformed stomach tube dosing in Xue et al. (2004). |
| Contact with gut lining | Direct contact with the mucosa before absorption. | Reaches the gut through the bloodstream. |
| Practitioner dose | 250 to 500 mcg once daily on an empty stomach. | 200 to 400 mcg once daily, subcutaneous or intramuscular. |
| Human trial data | No published randomized trial for any gut condition. | No published randomized trial for any gut condition. |
| FDA safety note | FDA has not approved oral BPC-157 for any use. | FDA flagged immune reaction risk for injected and nasal routes. |
Dosing Protocols in Practice
Because there are no approved human protocols, dosing in clinical practice is extrapolated from animal research and clinical experience. The protocols most commonly used by integrative medicine practitioners are as follows:
Oral Protocol (for GI Conditions)
- Dose: 250-500 mcg per day, taken on an empty stomach
- Duration: 4-8 weeks for acute conditions, ongoing for chronic GI issues
- Timing: Morning, 30 minutes before food, to maximize mucosal contact time
- Form: Capsules (lyophilized powder) from a compounding pharmacy or research chemical supplier
Injectable Protocol (for GI and Systemic Effects)
- Dose: 200-400 mcg subcutaneous or intramuscular injection, once daily
- Duration: 4-6 weeks
- Site: Subcutaneous injection near the area of concern for localized effects, or abdomen for general use
- Reconstitution: Bacteriostatic water, stored refrigerated, used within 30 days
These ranges are practitioner conventions, not doses established in human studies. The separate BPC-157 dosage overview covers dosing for tendon and soft tissue use, which is where most injectable protocols come from.
The Missing Human Data
The absence of human RCTs is the central limitation of BPC-157 and cannot be glossed over. Animal models of GI disease have a notoriously poor translation record to human medicine. Many compounds that heal rat gastric ulcers have failed or produced modest results in human trials. The gut biology of rodents and humans differs in important ways, including gastric acid production, microbiome composition, and mucosal immune responses.
The reason human trials have not been conducted is primarily regulatory and commercial. BPC-157 is not patentable in its current form, which reduces pharmaceutical industry incentive to fund the expensive trials needed for approval. Dr. Sikiric’s group has published extensively on animal data. According to Sikiric et al. (2012), BPC-157 under the code PL 14736 reached phase II testing for ulcerative colitis, but no full phase II report has appeared in a peer-reviewed journal and no phase III trial has followed as of 2025.
That clinical program for IBD, run with a Croatian drug company in the 1990s and 2000s, is described by the researchers as well tolerated, but it was never peer-reviewed or published in full. This does not constitute clinical evidence by modern standards.
Safety Profile
Animal toxicology studies from the developers’ laboratory show BPC-157 to be remarkably non-toxic even at very high doses. No LD50 (lethal dose) has been established in animal models, meaning it did not cause death even at extreme doses. There are no documented serious adverse events in the animal literature from that group.
FDA reads the safety data more cautiously. Its July 2026 Pharmacy Compounding Advisory Committee briefing cited repeat-dose toxicity studies in rats and dogs (Xu et al., 2020) that found statistically significant safety signals after 28 days of intramuscular dosing, and noted that an injected or nasal 15-amino-acid peptide may provoke immune reactions, a risk that aggregation and impurities can amplify.
In human use (extrapolating from community reports and integrative practitioners), the most common reported side effects are mild nausea and GI discomfort at higher doses, which is somewhat ironic given the GI healing indication. These appear to be dose-dependent and resolve with dose reduction.
The theoretical concern most often raised is BPC-157’s pro-angiogenic effects. Promoting blood vessel formation is generally beneficial for healing, but angiogenesis also supports tumor growth. There are no animal studies showing BPC-157 promotes cancer, and some studies actually show tumor-suppressing effects in specific models. However, anyone with active malignancy or a personal history of cancer should discuss this theoretical risk with their oncologist before considering use. The broader question of whether therapeutic peptides are safe applies here too: product quality often matters as much as the molecule.
Regulatory Status and Sourcing
BPC-157 is not FDA-approved for any indication. In the United States, it exists in a regulatory gray area. FDA placed BPC-157 in category 2 of bulk drug substances nominated for compounding on September 29, 2023, citing possible immunogenicity, peptide-related impurities and limited human safety data, according to FDA’s list of bulk drug substances that may present significant safety risks. That nomination was later withdrawn, and FDA’s advisory committee discussed new BPC-157 nominations for the 503A bulks list at its July 2026 meeting. Some compounding pharmacies continue to prepare it; others have stopped.
It is also sold as a “research chemical” by numerous online vendors with no prescription requirement. Quality control in this supply chain is highly variable. No regulator checks the purity, the sterility of injectables or the accuracy of the labeled dose. Anyone considering injectable forms should use a licensed compounding pharmacy with USP-grade materials and certificate of analysis documentation. Competitive athletes should also know that the World Anti-Doping Agency prohibits BPC-157 under its S0 class of non-approved substances.
For more on peptide-based approaches to gut health and overall healing, see our guides to peptide therapy and gut health and digestive wellness.
How BPC-157 Compares With Standard Gut Treatments
Standard treatments for inflammatory bowel disease, including mesalamine, corticosteroids, immunomodulators and biologic drugs such as anti-TNF antibodies, have randomized trial evidence and FDA approval for specific indications. BPC-157 has neither, so gastroenterologists treat it as an experimental add-on at most, not a replacement for established care.
Patients exploring other off-label options for gut inflammation often compare BPC-157 with the KPV peptide, which is also supported mainly by animal studies, and with low-dose naltrexone for Crohn’s disease, which has small human trials. The broader peptide therapy guide explains how these compounds differ in route, evidence and regulatory status.
Who Prescribes BPC-157 and How to Find a Clinician
BPC-157 is usually prescribed by integrative and functional medicine physicians, naturopathic doctors in states that allow them to prescribe, and some sports medicine and anti-aging practices. It is cash pay in nearly every case, because insurers do not cover unapproved compounds. Board-certified gastroenterologists generally rely on treatments with human trial data, so a clinician who offers BPC-157 should be willing to coordinate with your GI specialist.
Regenerated.com lists clinics that offer peptides in its national directory of peptide therapy clinics. Regenerated.com is free for patients, listing order is not paid ranking, Featured slots are labeled and capped, and Verified means credential checks rather than spend. Inclusion in the directory is not an endorsement. Before starting, ask any clinic these questions:
- Which pharmacy prepares the BPC-157, and will you share its certificate of analysis?
- Is the product oral or injectable, and why that route for my gut condition?
- How will you measure whether it is helping, and when will we stop if it is not?
- Will you share notes with my gastroenterologist or primary care physician?
Frequently asked questions
Is oral BPC-157 good for gut health?
Oral BPC-157 improved gut healing in rat studies of stomach ulcers, colitis and intestinal fistulas, partly because it stays stable in gastric juice for more than 24 hours. No randomized human trial has tested it for any gut condition, so its benefit in people is unknown. Most of the animal data comes from one research group at the University of Zagreb, and FDA has not approved BPC-157 for any use.
How much oral BPC-157 do people take for gut problems?
Integrative practitioners commonly use 250 to 500 mcg of oral BPC-157 once a day, taken on an empty stomach about 30 minutes before food, for 4 to 8 weeks. That range is extrapolated from animal studies that used 10 mcg/kg, which works out to about 700 mcg for a 70 kg adult. No human pharmacokinetic study has established a correct dose, so these numbers are conventions rather than tested protocols.
Is BPC-157 better taken orally or by injection for the gut?
Oral BPC-157 makes sense for the gut because it contacts the stomach and intestinal lining directly, and rat studies show it works by mouth. Injection is not clearly weaker for the gut, though: Xue et al. (2004) found intramuscular dosing reduced rat stomach ulcers more than dosing by stomach tube. FDA’s immune reaction concerns center on injected and nasal routes, which is one reason many practitioners start with capsules for gut complaints.
Is BPC-157 legal in the United States?
BPC-157 is not FDA approved for any indication, and its legal status for compounding is unsettled. FDA placed it in category 2 of risky bulk compounding substances in September 2023, the nomination was later withdrawn, and an FDA advisory committee discussed new nominations in July 2026. Research chemical vendors sell it without a prescription, but those products have no regulatory quality checks. WADA prohibits it for tested athletes.
Can BPC-157 help leaky gut, IBS or Crohn’s disease?
BPC-157 reduced intestinal permeability and colitis damage in animal models, which is why practitioners try it for leaky gut, IBS and Crohn’s disease. No published human trial supports any of these uses. A phase II ulcerative colitis program under the code PL 14736 was never published in full. Anyone with Crohn’s disease or ulcerative colitis should keep their established treatment and discuss BPC-157 with their gastroenterologist before adding it.
What are the side effects of BPC-157?
The side effects people report most often with BPC-157 are mild nausea and stomach discomfort at higher doses, which usually ease when the dose is lowered. Animal studies from the developers found no lethal dose, while FDA has cited safety signals in 28-day rat and dog studies and a risk of immune reactions to injected peptide. Because it promotes blood vessel growth, people with cancer or a history of cancer should ask their oncologist first.
